BACKGROUND AND RATIONALE: Research interests regarding the psychopharmacology of salvinorin A have been motivated by the recreational use and widespread media focus on the hallucinogenic plant, Salvia divinorum. Additionally, kappa opioid (KOP) receptor ligands may have therapeutic potential in the treatment of some neuropsychiatric conditions, including drug dependence and mood disorders. Salvinorin A is a selective KOP agonist, but only a few studies have explored the discriminative stimulus effects of this compound. OBJECTIVE: This study compared the discriminative stimulus effects of salvinorin A and two synthetic derivatives of salvinorin B to the KOP agonists, U69,593 and U50,488. MATERIALS AND METHODS: Sixteen male Sprague-Dawley rats trained to discriminate U69,593 (0.13 mg/kg, s.c., N = 8) or U50,488 (3.0 mg/kg, i.p., N = 8) under a fixed-ratio 20 schedule of food reinforcement were administered substitution tests with salvinorin A (0.125-3.0 mg/kg, i.p.). The animals trained to discriminate U69,593 were also administered substitution tests with salvinorin B ethoxymethyl ether (0.005-0.10 mg/kg, i.p.) and salvinorin B methoxymethyl ether (0.03-0.10 mg/kg, i.p.). Another eight rats were trained to discriminate 2.0 mg/kg salvinorin A and tested with U69,593 (0.04-0.32 mg/kg) and U50,488 (0.4-3.2 mg/kg). RESULTS: Salvinorin A and both synthetic derivatives of salvinorin B substituted completely for U69,593. Additionally, cross-generalization was observed between salvinorin A and both KOP agonists. CONCLUSION: These findings support previous reports indicating that the discriminative stimulus effects of salvinorin A are mediated by kappa receptors. Future studies may assist in the development and screening of salvinorin A analogs for potential pharmacotherapy.
BACKGROUND AND RATIONALE: Research interests regarding the psychopharmacology of salvinorin A have been motivated by the recreational use and widespread media focus on the hallucinogenic plant, Salvia divinorum. Additionally, kappa opioid (KOP) receptor ligands may have therapeutic potential in the treatment of some neuropsychiatric conditions, including drug dependence and mood disorders. Salvinorin A is a selective KOP agonist, but only a few studies have explored the discriminative stimulus effects of this compound. OBJECTIVE: This study compared the discriminative stimulus effects of salvinorin A and two synthetic derivatives of salvinorin B to the KOP agonists, U69,593 and U50,488. MATERIALS AND METHODS: Sixteen male Sprague-Dawley rats trained to discriminate U69,593 (0.13 mg/kg, s.c., N = 8) or U50,488 (3.0 mg/kg, i.p., N = 8) under a fixed-ratio 20 schedule of food reinforcement were administered substitution tests with salvinorin A (0.125-3.0 mg/kg, i.p.). The animals trained to discriminate U69,593 were also administered substitution tests with salvinorin B ethoxymethyl ether (0.005-0.10 mg/kg, i.p.) and salvinorin B methoxymethyl ether (0.03-0.10 mg/kg, i.p.). Another eight rats were trained to discriminate 2.0 mg/kg salvinorin A and tested with U69,593 (0.04-0.32 mg/kg) and U50,488 (0.4-3.2 mg/kg). RESULTS:Salvinorin A and both synthetic derivatives of salvinorin B substituted completely for U69,593. Additionally, cross-generalization was observed between salvinorin A and both KOP agonists. CONCLUSION: These findings support previous reports indicating that the discriminative stimulus effects of salvinorin A are mediated by kappa receptors. Future studies may assist in the development and screening of salvinorin A analogs for potential pharmacotherapy.
Authors: Christopher R McCurdy; Kenneth J Sufka; Grant H Smith; Jason E Warnick; Marcelo J Nieto Journal: Pharmacol Biochem Behav Date: 2006-01-23 Impact factor: 3.533
Authors: T Endoh; H Matsuura; A Tajima; N Izumimoto; C Tajima; T Suzuki; A Saitoh; T Suzuki; M Narita; L Tseng; H Nagase Journal: Life Sci Date: 1999 Impact factor: 5.037
Authors: Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek Journal: Psychopharmacology (Berl) Date: 2005-01-29 Impact factor: 4.530
Authors: William A Carlezon; Cécile Béguin; Jennifer A DiNieri; Michael H Baumann; Michele R Richards; Mark S Todtenkopf; Richard B Rothman; Zhongze Ma; David Y-W Lee; Bruce M Cohen Journal: J Pharmacol Exp Ther Date: 2005-10-13 Impact factor: 4.030
Authors: Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin Journal: Bioorg Med Chem Date: 2007-10-24 Impact factor: 3.641
Authors: Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth Journal: J Pharmacol Exp Ther Date: 2004-01-08 Impact factor: 4.030
Authors: Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell Journal: Eur J Pharmacol Date: 2013-11-04 Impact factor: 4.432
Authors: Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen Journal: Neuropharmacology Date: 2009-07-08 Impact factor: 5.250
Authors: Christina L Nemeth; Tracie A Paine; Joseph E Rittiner; Cécile Béguin; F Ivy Carroll; Bryan L Roth; Bruce M Cohen; William A Carlezon Journal: Psychopharmacology (Berl) Date: 2010-04-01 Impact factor: 4.530
Authors: D Matthew Walentiny; Robert E Vann; Jonathan A Warner; Lindsey S King; Herbert H Seltzman; Hernán A Navarro; Charles E Twine; Brian F Thomas; Anne F Gilliam; Brian P Gilmour; F Ivy Carroll; Jenny L Wiley Journal: Psychopharmacology (Berl) Date: 2010-03-31 Impact factor: 4.530
Authors: Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek Journal: Psychopharmacology (Berl) Date: 2010-01-19 Impact factor: 4.530
Authors: Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell Journal: J Pharmacol Exp Ther Date: 2020-09-10 Impact factor: 4.030
Authors: Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano Journal: Org Biomol Chem Date: 2009-07-14 Impact factor: 3.876